Moreover, recent studies suggested that silencing of PAPSS1 can enhance cisplatin activity in non-small cell lung cancer; also, PAPSS1 expression was negatively correlated with survival rate in patients receiving platinum-based chemotherapy [21, 22]. This evidence concerns the gene PAPSS1 and non-small cell lung carcinoma.